Previous 10 | Next 10 |
Enanta Pharmaceuticals (NASDAQ: ENTA ) announces positive results from a Phase 2a clinical trial, ARGON-1 , evaluating EDP-305 in patients with nonalcoholic steatohepatitis (NASH). More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...
Primary endpoint, ALT reduction at week 12, was met in the 2.5mg dosing group Key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, was met in the 2.5mg dosing group Conference call and webcast with slides to discuss the ARGON-1 data ...
Late-breaker oral presentation of EDP-938 on October 3 at 2:35 pm ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced th...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a firesi...
Enanta Pharmaceuticals, Inc. (ENTA) Q3 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Carol Miceli – Director-Investor Relations Jay Luly – President and Chief Executive Officer Paul Mellett – Chief Financial Officer Conferenc...
Enanta Pharma (NASDAQ: ENTA ): Q3 GAAP EPS of $0.33 beats by $0.19 . Revenue of $44.4M (-22.5% Y/Y) misses by $2.58M . Press Release More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Webcast and Conference Call today at 4:30 p.m. ET Royalty revenue for the quarter was $44.4 million Phase 2a NASH data expected by the end of the third calendar quarter Cash and marketable securities totaled $389.2 million at June 30, 2019 Enanta Pharmace...
The European Commission approves an eight-week regimen for AbbVie's (NYSE: ABBV ) MAVIRET (glecaprevir/pibrentasvir) for previously untreated patients with hepatitis C virus (HCV) genotypes 1,2,4,5 or 6 infection with compensated cirrhosis. It was previously approved as a 12-week regimen i...
MAVIRET™ is now available as a shorter, 8-week, once-daily option for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 or 6 Marketing authorization is supported by 97.9 percent cure* rate across this group of patient...
- MAVIRET ™ is now available as a shorter, 8-week, once-daily option for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 and 6 - Marketing authorization is supported by 97.9 percent cure * rate across this...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...